Eric Newman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric Newman has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Amy Miller
American College of Rheumatology Atlanta Georgia
1 shared publication- Amye Leong
Healthy Motivation, and Bone and Joint Decade, the Global Alliance for Musculoskeletal Health Santa Barbara California
1 shared publication Christine Chmielewski
Department of Medicine, Thomas Jefferson University, 2228 South Broad Street, Philadelphia, PA 19145, USA
1 shared publication- Claire E. H. Barber
Department of Community Health Sciences Cumming School of Medicine, University of Calgary Calgary Alberta Canada
1 shared publication - Edward John Filippone
Division of Nephrology, Department of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University
1 shared publication - Elena Losina
Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 9 May 2016
- Published by Wiley in Arthritis Care & Research
- Vol. 68 (10) , 1390-1401
American College of Rheumatology White Paper on Performance Outcome Measures in Rheumatology
Objective: To highlight the opportunities and challenges of developing and implementing performance outcome measures in rheumatology for accountability purposes.Methods: We constructed a hypothetical performance outcome measure to demonstrate the benefits and challenges of designing quality measures that assess patient outcomes. We defined the data source, measure cohort, reporting period, period at risk, measure outcome, outcome attribution, risk adjustment, reliability and validity, and reporting approach. We discussed outcome measure challenges specific to rheumatology and to fields where patients have predominantly chronic, complex, ambulatory care–sensitive conditions.Results: Our hypothetical outcome measure was a measure of rheumatoid arthritis disease activity intended for evaluating Accountable Care Organization performance. We summarized the components, benefits, challenges, and tradeoffs between feasibility and usability. We highlighted how different measure applications, such as for rapid cycle quality improvement efforts versus pay for performance programs, require different approaches to measure development and testing. We provided a summary table of key take‐home points for clinicians and policymakers.Conclusion: Performance outcome measures are coming to rheumatology, and the most effective and meaningful measures can only be created through the close collaboration of patients, providers, measure developers, and policymakers. This study provides an overview of key issues and is intended to stimulate a productive dialogue between patients, practitioners, insurers, and government agencies regarding optimal performance outcome measure development.
- 9 May 2016
- Published by Wiley in Arthritis Care & Research
- Vol. 68 (10) , 1390-1401
Open AccessAmerican College of Rheumatology White Paper on Performance Outcome Measures in Rheumatology
Objective: To highlight the opportunities and challenges of developing and implementing performance outcome measures in rheumatology for accountability purposes.Methods: We constructed a hypothetical performance outcome measure to demonstrate the benefits and challenges of designing quality measures that assess patient outcomes. We defined the data source, measure cohort, reporting period, period at risk, measure outcome, outcome attribution, risk adjustment, reliability and validity, and reporting approach. We discussed outcome measure challenges specific to rheumatology and to fields where patients have predominantly chronic, complex, ambulatory care–sensitive conditions.Results: Our hypothetical outcome measure was a measure of rheumatoid arthritis disease activity intended for evaluating Accountable Care Organization performance. We summarized the components, benefits, challenges, and tradeoffs between feasibility and usability. We highlighted how different measure applications, such as for rapid cycle quality improvement efforts versus pay for performance programs, require different approaches to measure development and testing. We provided a summary table of key take‐home points for clinicians and policymakers.Conclusion: Performance outcome measures are coming to rheumatology, and the most effective and meaningful measures can only be created through the close collaboration of patients, providers, measure developers, and policymakers. This study provides an overview of key issues and is intended to stimulate a productive dialogue between patients, practitioners, insurers, and government agencies regarding optimal performance outcome measure development.
- Open Access
- 13 June 2013
- Published by Wiley in Case Reports in Transplantation
- Vol. 2013, 1-5
De NovoFibrillary Glomerulonephritis (FGN) in a Renal Transplant with Chronic Hepatitis C
Chronic hepatitis C viremia (HepC) has been associated with numerous renal manifestations both in native kidneys and in the setting of renal transplantation. Glomerulonephritis (GN) of the renal allograft in the setting of HepC most commonly manifests as type 1 membranoproliferative GN (MPGN), either representing recurrence of the original disease or arisingde novo. Other GNs were reported after transplantation in the patient with HepC including membranous nephropathy and thrombotic microangiopathy, as well as an enhanced susceptibility to transplant glomerulopathy. We describe the first case ofde novofibrillary GN in a renal transplant patient with HepC where the primary renal disease was biopsy proven type 1 MPGN. We discuss this relationship in detail.
- 13 June 2013
- Published by Wiley in Case Reports in Transplantation
- Vol. 2013, 1-5
Open AccessDe NovoFibrillary Glomerulonephritis (FGN) in a Renal Transplant with Chronic Hepatitis C
Chronic hepatitis C viremia (HepC) has been associated with numerous renal manifestations both in native kidneys and in the setting of renal transplantation. Glomerulonephritis (GN) of the renal allograft in the setting of HepC most commonly manifests as type 1 membranoproliferative GN (MPGN), either representing recurrence of the original disease or arisingde novo. Other GNs were reported after transplantation in the patient with HepC including membranous nephropathy and thrombotic microangiopathy, as well as an enhanced susceptibility to transplant glomerulopathy. We describe the first case ofde novofibrillary GN in a renal transplant patient with HepC where the primary renal disease was biopsy proven type 1 MPGN. We discuss this relationship in detail.